177Lu-DOTA-ZOL治疗骨转移的安全性与剂量学评估
本研究前瞻性纳入9例mCRPC骨转移患者,单次给予5,780±329 MBq 177Lu-DOTA-ZOL后行SPECT/CT及血样监测。结果显示药物在骨病灶快速摄取并滞留,红骨髓为剂量限制器官,中位最大耐受活度6.0 GBq可能使部分患者红骨髓超过2 Gy阈值。
要点
- 177Lu-DOTA-ZOL在骨病灶快速摄取并滞留,血液清除快。
- 红骨髓为所有患者的剂量限制器官。
- 中位最大耐受活度6.0 GBq可能使部分患者红骨髓超过2 Gy。
核心结论
- 177Lu-DOTA-ZOL安全且相比其他骨转移治疗放射性药物具有有利的治疗指数。
- 个体化剂量学应被考虑以避免个别患者的严重血液毒性。
研究设计与样本
- 前瞻性研究纳入9例仅骨转移的mCRPC患者(70.8±8.4岁),常规治疗下进展。
- 单次给予5,780±329 MBq 177Lu-DOTA-ZOL后7天内行三维全身SPECT/CT成像和静脉血采样。
- 对主要器官和肿瘤病灶进行剂量学评估,通过血液生物标志物评估安全性。
主要发现
- 177Lu-DOTA-ZOL在所有患者中显示骨病灶快速摄取和高滞留,血液清除快。
- 注射后6小时肿瘤病灶平均滞留为0.02%注射活度/克,170小时约为0.01%。
- 骨肿瘤病灶、肾脏、红骨髓和骨表面的平均吸收剂量分别为4.21、0.17、0.36和1.19 Gy/GBq。
- 红骨髓在所有患者中为剂量限制器官。
关键数值与推荐
- 中位最大耐受注射活度为6.0 GBq,可能使个体患者(4/8)红骨髓超过定义的2 Gy阈值。
临床怎么用
- 177Lu-DOTA-ZOL可用于骨转移的姑息治疗,但需考虑个体化剂量学以避免严重血液毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Palliative treatment of bone metastasis using radiolabeled bisphosphonates is a well-known concept proven to be safe and effective. A new therapeutic radiopharmaceutical for bone metastasis is 177Lu-DOTA-zoledronic acid (177Lu-DOTA-ZOL). In this study, the safety and dosimetry of a single therapeutic dose of 177Lu-DOTA-ZOL were evaluated on the basis of a series of SPECT/CT images and blood samples. Methods: Nine patients with exclusive bone metastases from metastatic castration-resistant prostate cancer (mCRPC) (70.8 ± 8.4 y) and progression under conventional therapies participated in this prospective study. After receiving 5,780 ± 329 MBq 177Lu-DOTA-ZOL, patients underwent 3-dimensional whole-body SPECT/CT imaging and venous blood sampling over 7 d. Dosimetric evaluation was performed for main organs and tumor lesions. Safety was assessed by blood biomarkers. Results:177Lu-DOTA-ZOL showed fast uptake and high retention in bone lesions and fast clearance from the bloodstream in all patients. The average retention in tumor lesions was 0.02% injected activity per gram at 6 h after injection and approximately 0.01% at 170 h after injection. In this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfaces were 4.21, 0.17, 0.36, and 1.19 Gy/GBq, respectively. The red marrow was found to be the dose-limiting organ for all patients. A median maximum tolerated injected activity of 6.0 GBq may exceed the defined threshold of 2 Gy for the red bone marrow in individual patients (4/8). Conclusion:177Lu-DOTA-ZOL is safe and has a favorable therapeutic index compared with other radiopharmaceuticals used in the treatment of osteoblastic bone metastases. Personalized dosimetry, however, should be considered to avoid severe hematotoxicity for individual patients.
引用
- Fernández R, Eppard E, Lehnert W, et al. Evaluation of Safety and Dosimetry of 177Lu-DOTA-ZOL for Therapy of Bone Metastases. J Nucl Med. 2021. PMID: 33419945. doi:10.2967/jnumed.120.255851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。